Endeavor Launches With $62m And A Hedgehog Inhibitor From Lilly
Co-Founded By Former Impact Biomedicines CEO, Initial Focus Is IPF
John Hood spent the past few years looking for a drug candidate worth forming a new company around before he zeroed in on Lilly’s taladegib as a treatment for idiopathic pulmonary fibrosis.
You may also be interested in...
Inrebic, Celgene’s myelofibrosis treatment, and Yuflyma, Celltrion’s high-concentration adalimumab biosimilar, are among the latest new drugs that have been recommended for approval for use across the EU. Meanwhile, TETEC has withdrawn its EU marketing application for Artobend.
Start-up Impact's new structured financing – its second fundraising event this month – will pay out in increments as fedratinib nears the market. Also, Ablynx closed its $200m US IPO; Chi-Med follow-on brings in $262m; and VCs gives Cydan $34m to launch new companies.
Medicxi-funded Impact Biomedicines gave Sanofi a stake in the start-up to acquire fedratinib and bring the JAK2 inhibitor, which was placed on a clinical hold in 2013, to patients who are out of options.